Lactose (India) Ltd. (LACTOSE) Share Price Falls 8.12%: Price Action, Valuation and Sector View
- August 12, 2026
- Posted by: Harsh Piplani
- Category: News
Lactose (India) Ltd. Share Price is at Rs 105.25 on 12 August 2026, down Rs 9.30 or 8.12% from the previous close of Rs 114.55, taking the company’s market capitalisation to Rs 144.21 crore. In today’s Stock Market Today action, the move has put this micro-cap Healthcare name among stocks in news and underlined it as a top decliner in its segment.
The session data shows a sharp intraday retreat rather than a late marginal slip. The stock opened at Rs 117.80, which was also the day’s high, and then fell to an intraday low of Rs 105.00 before trading at Rs 105.25 at the time captured in the supplied data. Turnover stood at Rs 0.08 crore, while total traded volume was 7,491 shares, entirely on the BSE, where BSE volume was also 7,491 shares.
For readers searching Lactose (India) Ltd. Share Price Today, Lactose (India) Ltd. Stock News or Lactose (India) Ltd. Share Price Fall, the verified dataset confirms the price event but does not establish a company-specific catalyst. What it does establish is that the share price decline was meaningful enough to qualify under the workflow’s price-fall screen for its market-cap bucket, with the stock classified as a Micro Cap. That makes the move relevant not only as a price action update, but also as a starting point for deeper fundamental analysis, sector analysis and peer comparison. Univest notes that when a stock moves this sharply in a single session, investors usually look beyond the headline fall and examine valuation, profitability and broader industry positioning before drawing conclusions.
Lactose (India) Ltd. (LACTOSE) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 105.25 |
| Previous Close | Rs 114.55 |
| Today's Change | Rs -9.3 (-8.12%) |
| Day Open | Rs 117.8 |
| Day High | Rs 117.8 |
| Day Low | Rs 105 |
| Current Volume (BSE) | 7,491 |
| BSE Traded Volume | 7,491 |
| Combined NSE + BSE Volume | 7,491 |
| Turnover | Rs 0.08 crore |
| Market Capitalisation | Rs 144.21 crore |
| Market Cap Category | Micro Cap |
Lactose (India) Ltd. (LACTOSE) traded at Rs 105.25. versus the previous close of Rs 114.55, a fall of 8.12%. The stock opened at Rs 117.8, reached Rs 117.8, touched Rs 105. Reported volume was 7,491.
Lactose (India) Ltd. (LACTOSE) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 144.21 crore |
| P/E Ratio | 20.82x |
| P/B Ratio | 2.23x |
| ROE | -7.21% |
| ROCE | 2.81% |
| EPS | Rs 5.5 |
| Dividend Yield | 0% |
Lactose (India) Ltd. was valued at a P/E ratio of 20.82x, a P/B ratio of 2.23x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of -7.21% and ROCE of 2.81%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Per-share and shareholder-return metrics included EPS of Rs 5.5, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.
Lactose (India) Ltd. Share Price may be in focus because of today’s decline, but the underlying financial ratios present a mixed picture rather than a simple one-directional story. The stock trades at a P/E ratio of 20.82 and a P/B ratio of 2.23, while profitability indicators show ROE of -7.21% and ROCE of 2.81%. EPS stands at 5.5 and dividend yield is 0.
Starting with scale, the company’s market capitalisation is Rs 144.21 crore, placing it firmly in the micro-cap category. Market capitalisation indicates size, not quality, so this figure mainly frames the stock as a smaller listed player where trading moves can be more pronounced. On valuation, the P/E of 20.82 places the stock below the industry median P/E of 24.45 and far below the industry average of 79.31 in the same Pharmaceuticals & Drugs benchmark set. That does not by itself make the stock cheap, but it does show that its earnings multiple is below the central industry valuation reference supplied here.
The P/B ratio of 2.23 sits above the industry median P/B of 1.82, though below the industry average of 2.46. That suggests the market is assigning a book-value multiple modestly richer than the median company in the benchmark, even though profitability metrics are not especially strong. ROE at -7.21% is below both the benchmark median of 10.49% and average of 8.1%, while ROCE at 2.81% is also below the benchmark median of 12.97% and average of 15.64%. Those numbers indicate weaker capital efficiency than the broader peer universe captured in the supplied industry snapshot.
EPS of 5.5 means the company generated Rs 5.5 in earnings attributable to each share on the supplied basis. Against a current price of Rs 105.25, that connects directly to the 20.82 P/E multiple already visible in the valuation data. Dividend yield at 0 shows there is no current historical payout yield reflected in the supplied dataset, so the investment case, as far as this data goes, rests on business and valuation metrics rather than income distribution.
From a Univest stock analysis perspective, the combination is mixed: a sub-median P/E, a slightly above-median P/B, negative ROE and low ROCE. That combination neither confirms deep value nor supports a high-quality premium. It does, however, explain why investors tracking Lactose (India) Ltd. Share Price and Lactose (India) Ltd. Fundamental Analysis would want to compare the company carefully with its sector benchmark and listed peers before reading too much into one day’s market decline.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 20.82x |
| Benchmark Median P/E | 24.45x |
| Benchmark Average P/E | 79.31x |
| Benchmark P/E Range | 3.31x to 3,374.81x |
| Company P/B Ratio | 2.23x |
| Benchmark Median P/B | 1.82x |
| Company ROE | -7.21% |
| Benchmark Median ROE | 10.49% |
| Company ROCE | 2.81% |
| Benchmark Median ROCE | 12.97% |
| Company Market Capitalisation | Rs 144.21 crore |
| Benchmark Median Market Cap | Rs 146.94 crore |
Lactose (India) Ltd. (LACTOSE) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Lactose (India) Ltd. (LACTOSE) has a P/E ratio of 20.82x, which is below the benchmark median of 24.45x, a difference of -14.85%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Lactose (India) Ltd. (LACTOSE) has a ROE of -7.21%, which is below the benchmark median of 10.49%, a difference of -168.73%. Lactose (India) Ltd. (LACTOSE) has a ROCE of 2.81%, which is below the benchmark median of 12.97%, a difference of -78.33%.
Track today’s top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
The Healthcare sector and Pharmaceuticals & Drugs industry benchmark provide useful context for today’s move. In the supplied same-industry comparison set of 136 companies, Lactose (India) Ltd. carries a P/E of 20.82, below the median of 24.45 and well below the average of 79.31. However, its ROE of -7.21% and ROCE of 2.81% trail benchmark profitability levels.
Lactose (India) Ltd. operates in Healthcare, specifically in Pharmaceuticals & Drugs. The benchmark scope is described as the same industry, covering 136 companies for market capitalisation comparisons, 104 companies for P/E, 135 for P/B, 135 for ROE and 135 for ROCE. That is broad enough to give investors a numerical frame for sector analysis without relying on general assumptions about the Indian Stock Market.
On valuation, the company P/E of 20.82 is below the benchmark median of 24.45 and dramatically below the benchmark average of 79.31. The industry P/E range itself is wide, stretching from 3.31 to 3,374.81, which suggests dispersion in profitability and market expectations across Pharmaceuticals & Drugs names. Lactose (India) Ltd.’s P/B ratio of 2.23 is above the benchmark median of 1.82, but below the average of 2.46, placing it near the middle of the valuation band rather than at an extreme. The industry P/B range runs from -16.74 to 16.32.
Profitability is where the contrast becomes clearer. The company’s ROE of -7.21% is lower than the benchmark median of 10.49% and the average of 8.1%. Its ROCE of 2.81% is also materially below the industry median of 12.97% and average of 15.64%. In other words, the stock’s earnings multiple is not high relative to the sector, but the return profile is also weaker than the benchmark.
Size is another useful lens. Lactose (India) Ltd. has a market cap of Rs 144.21 crore, close to but slightly below the benchmark median market capitalisation of Rs 146.94 crore and far below the benchmark average of Rs 484.32 crore. The industry range spans from Rs 6.31 crore to Rs 2,949.87 crore. For Univest readers following Lactose (India) Ltd. Market Cap and sector positioning, that means the company sits near the lower-middle end of the size spectrum in this industry set, not at the extreme bottom, but well below the larger listed peers that often dominate sector narratives.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,949.87 | 31.07 | 0.45 | -2.89 | -0.26 |
| Beta Drugs Ltd. | BETA | 2,775.9 | 71.31 | 11.28 | 18.65 | 22.17 |
| Hikal Ltd. | HIKAL | 2,761.32 | 0 | 2.26 | 15.22 | 16.15 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,594.65 | 179.52 | 3.32 | 13.9 | 12.97 |
| Solara Active Pharma Sciences Ltd. | SOLARA | 2,474.65 | 0 | 1.92 | 17.23 | 15.34 |
Lactose (India) Ltd. (LACTOSE) has a P/E ratio of 20.82x compared with the displayed peer median of 31.07x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -7.21% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 2.81% versus the displayed peer median of 15.34%, providing a capital-efficiency comparison. Lactose (India) Ltd. (LACTOSE) has a market capitalisation of Rs 144.21 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Peer data shows Lactose (India) Ltd. is much smaller than the listed Pharmaceutical peers supplied in the dataset, and its profitability metrics compare less favourably with many of them. Its P/E of 20.82 is lower than several peers, but its ROE of -7.21% and ROCE of 2.81% trail many companies in the comparison set.
Consider Dishman Carbogen Amcis Ltd., which has a market cap of Rs 2,949.87 crore, P/E of 31.07, P/B of 0.45, ROE of -2.89% and ROCE of -0.26%. Compared with that, Lactose (India) Ltd. trades at a lower earnings multiple and a much higher P/B ratio, while its ROE is weaker and its ROCE is higher. That already shows why peer reading needs nuance: lower P/E alone does not settle the quality question.
Beta Drugs Ltd. presents a very different profile, with market cap of Rs 2,775.90 crore, P/E of 71.31, P/B of 11.28, ROE of 18.65% and ROCE of 22.17%. Relative to Beta Drugs, Lactose (India) Ltd. looks far less expensive on P/E and P/B, but it also has substantially weaker returns. NGL Fine-Chem Ltd. tells a similar story, with market cap of Rs 2,140.53 crore, P/E of 44.41, P/B of 6.49, ROE of 27.9% and ROCE of 33.91%, again showing that stronger profitability often coincides with richer valuation.
Hester Biosciences Ltd., with market cap of Rs 2,128.33 crore, P/E of 15.51, P/B of 4.64, ROE of 16.17% and ROCE of 14.12%, is notable because it combines a lower P/E than Lactose (India) Ltd. with significantly stronger returns. That comparison may stand out to investors scanning Lactose (India) Ltd. Stock Analysis for relative valuation efficiency. Ind-Swift Laboratories Ltd., meanwhile, has market cap of Rs 2,061.86 crore, P/E of 43.16, P/B of 1.65, ROE of -0.78% and ROCE of 8.31%. Here, Lactose (India) Ltd. has the lower P/E, higher P/B, weaker ROE and lower ROCE.
Other names in the supplied peer universe include Sai Parenteral’s Ltd. with P/E of 179.52 and ROCE of 12.97%, Solara Active Pharma Sciences Ltd. with P/B of 1.92 and ROCE of 15.34%, Panacea Biotec Ltd. with P/B of 2.95 and ROCE of 5.36%, Hikal Ltd. with P/B of 2.26, ROE of 15.22% and ROCE of 16.15%, and Indoco Remedies Ltd. with P/E of 355.2, P/B of 1.99, ROE of 12.85% and ROCE of 15.67%. Across this set, the main takeaway is consistent: Lactose (India) Ltd. Share Price is attached to a smaller company with a middling valuation profile but comparatively weak return ratios.
Why Investors Are Watching Lactose (India) Ltd.
Lactose (India) Ltd. Share Price is being watched because today’s fall was large enough to place the stock in the top losers conversation, while the underlying financial and sector data create a mixed analytical picture. The stock is not trading on an obviously stretched earnings multiple relative to its industry median, but profitability ratios remain below benchmark levels. For market participants, that combination keeps the stock relevant in market news and stock updates.
- Verified price action: The stock declined 8.12% to Rs 105.25 from Rs 114.55, after opening at Rs 117.80 and touching a low of Rs 105.00.
- Trading participation: BSE volume was 7,491 shares and turnover was Rs 0.08 crore, enough to register a notable move in a micro-cap counter.
- Valuation context: P/E is 20.82, below the industry median of 24.45, while P/B is 2.23 versus an industry median of 1.82.
- Profitability context: ROE is -7.21% and ROCE is 2.81%, both below same-industry medians.
- Sector position: Market cap of Rs 144.21 crore is slightly below the benchmark median of Rs 146.94 crore in the Pharmaceuticals & Drugs set.
What investors may monitor next is whether Lactose (India) Ltd. Share Price stabilises near the day low zone or remains under pressure after this single-session decline, and whether future company financials improve return metrics relative to sector norms. Univest would frame the stock as one requiring close monitoring of both price action and business-quality indicators, not just the headline move.
About Lactose (India) Ltd.
Lactose (India) Ltd. belongs to the Healthcare sector and operates within the Pharmaceuticals & Drugs industry. Based on the supplied data, the clearest verified context is that the company is part of a broad listed pharmaceutical universe in which business models and profit profiles vary widely, as reflected by the very broad range of valuation and return ratios across the same-industry benchmark.
Its current market capitalisation of Rs 144.21 crore places it close to the median-sized company in the 136-company benchmark set, though still far smaller than peers such as Dishman Carbogen Amcis, Beta Drugs, Hikal, Sai Parenteral’s and Solara Active Pharma Sciences, all of which have market caps above Rs 2,400 crore except Hester Biosciences and Ind-Swift Laboratories, which still remain well above Rs 2,000 crore. That size difference matters because smaller listed pharmaceutical stocks can often see sharper day-to-day price action when trading volumes are concentrated.
For readers looking for Lactose (India) Ltd. Company News, Lactose (India) Ltd. NSE, Lactose (India) Ltd. BSE or Lactose (India) Ltd. Latest News style queries, today’s update is primarily a market move story rather than a disclosed business-event story in the supplied feed. What can be said factually is that the company sits in a closely watched Healthcare segment, where valuation and return comparisons are essential. Univest therefore views the stock through three basic lenses supported by data here: micro-cap size, below-median industry P/E and weak relative profitability.
Track Lactose (India) Ltd. Share Price on Univest
Use Lactose (India) Ltd. (LACTOSE) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.
Investors following Lactose (India) Ltd. Share Price Today can use Univest to track live share price movements, market cap changes, valuation ratios such as P/E and P/B, profitability indicators including ROE and ROCE, and broader market insights around sector positioning. Univest also helps readers monitor 52-week levels when available, peer comparisons, shareholding pattern data when disclosed, and intraday stock performance indicators that matter during sessions marked by market decline or selling pressure.
For users searching Lactose (India) Ltd. Share Price Live, Lactose (India) Ltd. Share News or Lactose (India) Ltd. Stock News, the value lies in combining one-day price action with ongoing financial analysis. That gives a more complete view than reacting only to a single session’s fall.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Lactose (India) Ltd. Share Price today?
Ans. Lactose (India) Ltd. Share Price today is Rs 105.25. The stock was down Rs 9.30 or 8.12% from the previous close of Rs 114.55 at the time captured in the supplied market data.
Why is Lactose (India) Ltd. Share Price falling today?
Ans. The supplied data confirms that the stock fell 8.12% in the session and qualified on a price-fall screen for its Micro Cap category. However, the dataset does not establish a company-specific catalyst for the decline.
What were the day high, day low and opening price for Lactose (India) Ltd.?
Ans. The stock opened at Rs 117.80, which was also the day high. It later declined to a day low of Rs 105.00 before trading at Rs 105.25 in the supplied intraday snapshot.
How much market capitalisation does Lactose (India) Ltd. have?
Ans. Lactose (India) Ltd. has a market capitalisation of Rs 144.21 crore. In the supplied classification, it falls under the Micro Cap category, which helps explain why investors track sharp single-day price movements closely.
What does the valuation of Lactose (India) Ltd. look like?
Ans. The stock is valued at a P/E ratio of 20.82 and a P/B ratio of 2.23. Its P/E is below the same-industry median of 24.45, while its P/B is above the industry median of 1.82.
How profitable is Lactose (India) Ltd. compared with its industry benchmark?
Ans. The company’s ROE is -7.21% and ROCE is 2.81%. Both are below the same-industry medians of 10.49% for ROE and 12.97% for ROCE, indicating weaker profitability relative to the benchmark set.
What were the trading volume and turnover in Lactose (India) Ltd. today?
Ans. Total traded volume was 7,491 shares, and the supplied feed shows BSE volume of 7,491 shares as well. Turnover stood at Rs 0.08 crore, highlighting a noticeable move within a relatively low-value session.
Does Lactose (India) Ltd. pay a dividend?
Ans. The supplied data shows a dividend yield of 0. That means no current historical payout yield is reflected in this dataset, so the stock’s tracked metrics here are more valuation- and profitability-led.
How does Lactose (India) Ltd. compare with larger pharma peers?
Ans. Lactose (India) Ltd. is much smaller than peers such as Dishman Carbogen Amcis, Beta Drugs and Hikal, all above Rs 2,700 crore in market cap. Its return ratios are also lower than many supplied Pharmaceuticals & Drugs peers.
What should investors monitor next in Lactose (India) Ltd. Stock News?
Ans. Investors may watch whether the stock stabilises after falling from Rs 117.80 to near Rs 105.00 intraday, and whether future financial performance improves ROE and ROCE relative to the Healthcare industry benchmarks.
